CanSino Biologics co-founder Qiu Dongxu said the company is in talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial of its experimental COVID-19 vaccine, as reported Fidelity on Saturday.
He said the study was likely to start "pretty soon," and the company plans to recruit 40,000 participants.
CanSino Biologics' COVID-19 candidate, Ad5-nCov, became the first in China to move into clinical trials in March but is running behind other potential vaccines in terms of trial progress.
Two experimental vaccines developed by Sinovac Biotech and a unit of China National Pharmaceutical Group (Sinopharm) are already approved for Phase III trials.
Qiu said its Phase II trial involving 508 people yielded "much better" results than the Phase I study, adding that the company's new factory under construction in China will allow it to produce 100 to 200 million doses of COVID-19 vaccines per year by early 2021.
To read more NewsPoints articles, click here.